NVS Jan 2024 120.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 09:44AM EST. Market open.
Loading interactive chart…
- Yahoo Finance UK
Trending tickers: Rolls-Royce | Novartis | EasyJet | Barclays
The latest investor updates on stocks that are trending on Tuesday.
- GlobeNewswire
Novartis upgrades mid-term sales growth guidance, showcases its differentiated innovative medicines strategy and robust pipeline at R&D Day
Ad hoc announcement pursuant to Art. 53 LR ‘Pure-play’ innovative medicines strategy focused on four therapeutic areas and five technology platforms, which offer potential for consistent growth Mid-term sales guidance upgrade to 5% CAGR (2022-27), with core operating income margin of ~40%+ by 2027, driven by continued strong momentum of key growth drivers Confidence to grow mid-single digit longer-term based on the foundational strength of de-risked existing brands and pipeline assets Focused st
- Zacks
Olema Pharmaceuticals (OLMA) Skyrockets 471% YTD: Here's Why
Olema's (OLMA) shares surge on the successful development of its lead candidate in metastatic breast cancer indication.
© 2023 Yahoo. All rights reserved.